• Vaxil Bio (TSXV:VXL) has announced a brokered private placement for gross proceeds of up to C$3 million
  • The company plans to issue up to 35.2 million units at a price of 8.5 cents each
  • M Partners Inc has been engaged to act as the lead agent and sole bookrunner for the placement
  • The proceeds will be used to fund pre-clinical research supporting the company’s pipeline of products
  • Vaxil Bio (VXL) is currently down 10 per cent and is trading at nine cents per share, with a market cap of $9.25 million

Vaxil Bio (TSXV:VXL) has announced a brokered private placement for gross proceeds of up to C$3 million.

The Israeli immunotherapy biotech company is currently focused on its novel approach to targeting significant cancer markers and infectious diseases.

Through its engagement of M Partners Inc as lead agent and sole book runner of the placement, Vaxil will issue up to 35,294,118 units at a price of 8.5 cents each. The receipt of the $3 million in gross proceeds is subject to a minimum sale of 23,529,412, or roughly $2 million.

Each unit will consist of one common share in the company, as well as one common share purchase warrant. These warrants will entitle the holder to acquire an additional common share at a price of $0.13, exercisable for a period of three years from the date of issuance.

Vaxil will also pay M Partners a cash commission of up to 7 per cent of the gross proceeds raised under the placement.

Non-transferable warrants will also be issued, equal to 7 per cent of the total number of units sold. These will be exercisable at a price of 8.5 cents over a period of three years from the date of closing.

Upon closing of the placement, Vaxil will used the proceeds to fund pre-clinical research supporting the development of its current pipeline of products. This includes its COVID-19 vaccine candidate, oncology and other infectious disease immunotherapies.

David Goren, Chairman and CEO of Vaxil Bio, said the financing comes at a critical time for the company.

“These additional funds will allow us to more aggressively advance our preclinical research program including the COVID-19 vaccine, whilst continuing to pursue our other pipeline candidates such as vaccines for other infectious diseases and our ongoing work in oncology.

“We look forward to our continued collaborations with the Tel-Aviv Medical Centre where are progressing our COVID-19 research and Ben Gurion University for their role in our oncology program,” he said.

Vaxil Bio (VXL) is currently down 10 per cent and is trading at nine cents per share at 12:37pm EDT.

More From The Market Online

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.
WELL Health - Hamed Shahbazi, Founder and CEO (third from right).

WELL Health streamlining business towards profitable growth

WELL Health (TSX:WELL) has made an integration update to streamline its business operations and position itself for profitable growth.

An investor’s gateway into the cancer immunotherapy market is with this Canadian biotechnology company 

The overarching cancer immunotherapy market continues growing at unprecedented rates, and BioVaxys Technology is ready to capitalize on it.

Buzz on the Bullboards: Where volatility meets opportunity

Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day.